• Contact us
  • Advertising Policy
  • Cookie Policy
  • Disclaimer
  • Privacy Policy
  • Terms of Use
Saturday, July 19, 2025
25 °c
Agartala
enewstime
  • Home
  • News
    • Northeast
    • National
    • International
    • Tripura News
  • Sports
    Bumrah should feature in both the remaining Tests: Kumble

    Bumrah should feature in both the remaining Tests: Kumble

    Gill being fired up at Lord’s didn’t have the right effect on his batting returns, says Manjrekar

    Gill being fired up at Lord’s didn’t have the right effect on his batting returns, says Manjrekar

    Jadeja hailed as Team India's MVP after incredible fight at Lord’s

    Jadeja hailed as Team India's MVP after incredible fight at Lord’s

    'Win the toss and bat, put runs on the board': Kaif advises Gill to follow Kohli’s approach  

    'Win the toss and bat, put runs on the board': Kaif advises Gill to follow Kohli’s approach  

    Arsenal sign Olivia Smith for world-record women's transfer fee

    Arsenal sign Olivia Smith for world-record women's transfer fee

    When we played on gravel pitches in Brazil, I'd imagine playing for United: Matheus Cunha

    When we played on gravel pitches in Brazil, I'd imagine playing for United: Matheus Cunha

    I knew with calm and composed approch we can pull off the chase: Deepti Sharma

    I knew with calm and composed approch we can pull off the chase: Deepti Sharma

    'Aussie Ashes line-up is going to be like it is right now', opines Ponting

    'Aussie Ashes line-up is going to be like it is right now', opines Ponting

    Jitesh Sharma to represent Baroda in 2025/26 domestic season after leaving Vidarbha

    Jitesh Sharma to represent Baroda in 2025/26 domestic season after leaving Vidarbha

  • Business
  • Entertainment
  • Health
  • Features
  • TendersNew
No Result
View All Result
  • Home
  • News
    • Northeast
    • National
    • International
    • Tripura News
  • Sports
    Bumrah should feature in both the remaining Tests: Kumble

    Bumrah should feature in both the remaining Tests: Kumble

    Gill being fired up at Lord’s didn’t have the right effect on his batting returns, says Manjrekar

    Gill being fired up at Lord’s didn’t have the right effect on his batting returns, says Manjrekar

    Jadeja hailed as Team India's MVP after incredible fight at Lord’s

    Jadeja hailed as Team India's MVP after incredible fight at Lord’s

    'Win the toss and bat, put runs on the board': Kaif advises Gill to follow Kohli’s approach  

    'Win the toss and bat, put runs on the board': Kaif advises Gill to follow Kohli’s approach  

    Arsenal sign Olivia Smith for world-record women's transfer fee

    Arsenal sign Olivia Smith for world-record women's transfer fee

    When we played on gravel pitches in Brazil, I'd imagine playing for United: Matheus Cunha

    When we played on gravel pitches in Brazil, I'd imagine playing for United: Matheus Cunha

    I knew with calm and composed approch we can pull off the chase: Deepti Sharma

    I knew with calm and composed approch we can pull off the chase: Deepti Sharma

    'Aussie Ashes line-up is going to be like it is right now', opines Ponting

    'Aussie Ashes line-up is going to be like it is right now', opines Ponting

    Jitesh Sharma to represent Baroda in 2025/26 domestic season after leaving Vidarbha

    Jitesh Sharma to represent Baroda in 2025/26 domestic season after leaving Vidarbha

  • Business
  • Entertainment
  • Health
  • Features
  • TendersNew
No Result
View All Result
enewstime
  • Home
  • News
  • Sports
  • Business
  • Entertainment
  • Health
  • Features
  • Tenders
Home Health

Indian experts hail ‘promising’ mRNA vax for Covid treatment

ENEWSTIME Desk by ENEWSTIME Desk
November 17, 2020
in Health
30
VIEWS
Share on FacebookShare on Twitter

BY BHARAT UPADHYAY

With the two mRNA vaccine candidates from pharma giants Pfizer-BioNTech and Moderna showing effectiveness in preventing Covid-19 in an interim analysis, health experts in India on Tuesday said that mRNA vaccine that works on previously unproven technology can be very promising in the fight against the pandemic despite the challenges.

To date, no mRNA vaccine has been licensed for infectious diseases and if an mRNA vaccine is approved for coronavirus, it would be the first of its type.

mRNA (messenger RNA) vaccines trick the body into producing some of the viral proteins itself.

They work by using mRNA, which is the molecule that essentially puts DNA instructions into action.

Inside a cell, mRNA is used as a template to build a protein.

Both Moderna and Pfizer-BioNTech use the mRNA technology which means the vaccine is not embedded with the virus itself and, therefore, no risk of catching Covid-19 from the shot itself.

The vaccine is infused with a piece of genetic code that trains our immune system to recognize the spike protein on the surface of the virus — a lethal signature of the coronavirus.

According to Dr Monika Gupta, Senior Consultant, Microbiologist at Fortis Hospital in New Delhi, unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence (the molecule which tells cells what to build) which is coded for a disease-specific antigen (like SARS-CoV-2, the coronavirus), once produced within the body, the antigen is recognised by the immune system, preparing it to fight the real thing.

“RNA vaccines are faster and cheaper to produce than traditional vaccines and an RNA-based vaccine is also safer for the patient, as they are not produced using infectious elements,” Gupta told IANS.

Production of RNA vaccines is laboratory-based, and the process could be standardised and scaled, allowing quick responses to large outbreaks and epidemics.

“A major advantage of RNA vaccines is that RNA can be produced in the laboratory from a DNA template using readily available materials, less expensively and faster than conventional vaccine production,” she explained.

Dr Gupta added that the vaccine based on mRNA, once injected into the body, will instruct the body’s cells to create copies of the spike protein. In turn, this is expected to prompt the immune cells to create antibodies to fight it.

“These antibodies will remain in the blood and fight the real virus if and when it infects the human body,” she stressed.

Dr Naveen Aggarwal, Head and Senior Consultant, Pathologist, Action Cancer Hospital in New Delhi said that as per the basic mechanism, the mRNA vaccines are Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for protein like spike protein of Covid-19 virus.

“Hence it can be said that mRNA vaccines are very much promising in the fight against the Covid 19 pandemic as the efficacy claims between 90 to 95 per cent by various manufacturers, however, results of the trial are still awaited,” he said.

According to Dr Gitali Bhagawati, Consultant and Head, Department of Microbiology and Infection Control, Dharamshila Narayana Superspeciality Hospital, advantages of the mRNA vaccine are that it is faster in development, cheaper to produce, safer for the protein routes via needle or needle-free (nasal spray).

“As far as the challenges, the mRNA vaccine is temperature sensitive, it needs to be stored at below 70 degrees Celsius which will be a challenging task for remote areas,” she added.

Aggarwal told IANS: “For a country like India, the maintenance of ultra-cold chains and its role in the prevention of the spread of infection is yet to be established.”

On Monday, the US pharma giant Moderna announced that its messenger RNA (mRNA) vaccine has shown 94.5 per cent efficacy against Covid-19 in preliminary data from the company’s ongoing study.

The news comes exactly after US-based pharmaceutical major Pfizer and German biotech firm BioNTech said their respective Covid-19 vaccine candidate, also created using mRNA technology, was more than 90 per cent effective in its own 60,000-patient clinical trial.

According to an article in the Science journal, both mRNA vaccines have yet to complete their efficacy trials, which aim to accrue about 150 to 165 cases of Covid-19 to provide greater statistical certainty of any efficacy result.

“But they should hit those targets by December, when FDA plans to convene an advisory committee to review the data, as most trial sites are in the United States, where the epidemic is exploding”.

(Bharat Upadhyay can be reached at bharat.u@ians.in)

Related Posts

Twin studies report global rise in gastrointestinal cancers among middle-aged adults
Health

Twin studies report global rise in gastrointestinal cancers among middle-aged adults

July 18, 2025
Vietnam issues directive to curb African swine fever outbreaks
Health

Vietnam issues directive to curb African swine fever outbreaks

July 18, 2025
Explained: What is 'chronic venous insufficiency' that Donald Trump is suffering from
Health

Explained: What is 'chronic venous insufficiency' that Donald Trump is suffering from

July 18, 2025
South Africa rolls out mpox vaccination programme to curb spread
Health

South Africa rolls out mpox vaccination programme to curb spread

July 18, 2025
Climate, wildlife key predictors of bird flu outbreaks in Europe: Study
Health

Climate, wildlife key predictors of bird flu outbreaks in Europe: Study

July 18, 2025
Gene essential for vitamin D absorption may boost cancer treatment
Health

Gene essential for vitamin D absorption may boost cancer treatment

July 18, 2025
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
D-2050 D-2050 D-2050
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

About us

Enewstime.in is run by an individual – a Journalist by profession of Tripura with the active help of several journos including senior journalists of the State. On top of that, Enewstime.in being a subscriber of IANS news agency, we have plenty of multi-choice topics to offer to our esteemed readers. Enewstime.in is a venture reach global audience from a tiny State Tripura.

Latest News

Twin studies report global rise in gastrointestinal cancers among middle-aged adults

Vietnam issues directive to curb African swine fever outbreaks

Kaveri Kapur opens up about her battle with PCOS & Uranium Poisoning; Admits 'Feeling better now'

Indian stock market ends lower amid selling in banking, IT sectors

Bumrah should feature in both the remaining Tests: Kumble

Explained: What is 'chronic venous insufficiency' that Donald Trump is suffering from

Contact us

19, Old Thana Road. Banamalipur. PO. Agartala. Pin code 799001. Tripura (West), India.

Email: enewstime2017@gmail.com

Wa: 8794548041

  • Contact us
  • Advertising Policy
  • Cookie Policy
  • Disclaimer
  • Privacy Policy
  • Terms of Use

© 2025 Designed & Developed with ❤️ by Provibe Media LLP

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Northeast
    • National
    • International
    • Tripura News
  • Sports
  • Business
  • Entertainment
  • Health
  • Features
  • Tenders

© 2025 Designed & Developed with ❤️ by Provibe Media LLP